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to better understand patients’ experiences. This symptom could be 
taken into account in the quality of life scale. Pruritus is a poorly 
known but crucial symptom of NF1.
CLINICAL RESEARCH TRACK – 
THERAPEUTICS
PP22
SAFETY AND ANTI-PRURITIC EFFICACY OF 
A MENTHOL-CONTAINING MOISTURIZING 
CREAM
Wei-Sheng Chong, Hong Liang Tey
National Skin Center, Singapore
Background: Itch is frequently associated with dermatoses charac-
terized by a defective skin barrier. We formulated an itch-relieving 
moisturizing cream containing 3% menthol and ceramides. Aims: 
To evaluate the safety and anti-pruritic efficacy of application of 
this cream in volunteers with and without skin diseases. Methods: 
Volunteers were to apply the cream for 1 month on a minimum 
body surface area of 6%. Safety was assessed by the absence of 
contact dermatitis or other side effects, using a self-administered 
questionnaire administered at 5 minutes, 1 week and 1 month after 
application. To assess efficacy, volunteers with pruritic dermatoses 
were to grade their average itch intensity at baseline, 1 week and 1 
month after application. Results: Sixty volunteers were recruited, 
of whom 41 had no skin disease. There were no adverse events 
reported in the latter. Of the 19 volunteers with dermatoses, 18 
reportedly had eczema. One stopped application due to stinging 
sensations induced by menthol. Itch scores of volunteers with 
eczema improved from baseline at 1 week (p=0.01) and 1 month 
(p<0.01) after application. Conclusion: Application of a 3% 
menthol-containing moisturizing cream was safe in healthy indi-
viduals and individuals with eczema. In the latter, application of 
the cream significantly reduced itch scores.
PP23
PLEIOTROPIC ACTION OF CYCLOSPORINE ON 
PRURITUS OF ATOPIC DERMATITIS
Mitsutoshi Tominaga1, Kyi Chan Ko1, Yayoi Kamata1, Yoshie 
Umehara1, Hironori Matsuda1, Nobuaki Takahashi1, Katsunari 
Kina1, Mayuko Ogawa1, Hideoki Ogawa1, Kenji Takamori1,2
1Institute for Environmental and Gender Specific Medicine, Juntendo Uni-
versity Graduate School of Medicine, Urayasu, 2Department of Dermato-
logy, Juntendo University Urayasu Hospital, Urayasu, Japan
Cyclosporine A (CsA) is currently used in treatment of patients 
with severe atopic dermatitis (AD) and suppresses the pruritus, 
although its antipruritic mechanism is poorly understood. This 
study was performed to reveal the antipruritic mechanism of 
CsA in AD using a mouse model of AD induced by repeated 
application of house dust mite Dermatophagoides farinae body 
(Dfb) ointment (Dfb-NC/Nga). Intraperitoneal injection of 5 mg/
kg CsA significantly reduced epidermal nerve density, number of 
scratching bouts, dermatitis scores, and transepidermal water loss, 
as well as decreasing the numbers of CD4+ T cells, mast cells, 
and eosinophils in the dermis and decreasing epidermal thickness. 
Moreover, intraperitoneal injection of CsA dose-dependently 
inhibited increased itch-related receptor gene expression, such as 
interleukin-31 receptor A (IL-31RA) and neurokinin-1 receptor 
(NK1R), in the dorsal root ganglion (DRG) of Dfb-NC/Nga mice. 
Thus, the therapeutic efficacy of CsA in pruritus of AD may involve 
reduced epidermal nerve density and expression levels of IL-31RA 
and NK1R in the DRG as well as improvement of acanthosis and 
reduction of cutaneous inflammatory cell numbers.
PP24
DECREASE OF ITCH INTENSITY BY CR845, A 
NOVEL KAPPA OPIOID RECEPTOR AGONIST 
Robert Spencer1, Vandana Mathur2, Joseph W. Stauffer1, Fré-
dérique Menzaghi1
1Cara Therapeutics, Inc., Shelton, Connecticut, 2MathurConsulting, San 
Francisco, California, USA
Kappa opioid agonists are known to modulate pruritus and the 
mixed non-selective mu partial agonist/kappa opioid agonist 
nalfurafine (Remitch™) is marketed in Japan for the treatment of 
uremic pruritus (UP) in hemodialysis patients. CR845 is a new 
kappa opioid receptor agonist being developed for the treatment of 
UP. In addition to its unique receptor profile (no activity at mu- or 
delta-opioid receptors), the peptidic structure of CR845 restricts 
its entry into the central nervous system and differentiates it from 
other therapies such as nalfurafine. A dose-dependent, sustained 
anti-itch activity was demonstrated for CR845 using in vivo mouse 
models of itch (induced by the selective KOR antagonist, 5’-GNTI, 
and the mast cell secretagogue, compound 48/80). IV CR845 was 
also evaluated in a double-blind, randomized, placebo-controlled 
trial in the US with 65 patients with moderate to severe UP. At 
the end of a two-week treatment period (administration 3 times/
week after each dialysis), a significant reduction in itch intensity 
(as measured by a visual analog scale) was reported in patients 
receiving CR845 (1 µg/kg, n=33) compared to those receiving 
placebo (p=0.016, n=32). These results provide evidence that se-
lective activation of peripheral kappa opioid receptors reduces itch.
CLINICAL RESEARCH TRACK – 
CLINICAL CASES
PP25
CONSIDERABLE VARIABILITY IN THE 
EFFICACY OF 8% CAPSAICIN TOPICAL PATCHES 
IN THE TREATMENT OF CHRONIC PRURITUS IN 
3 NOTALGIA PARESTHETICA PATIENTS 
Hjalte H. Andersen1, Carsten Sand2, Jesper Elberling3
1SMI, Department of Health science and Technology, Faculty of Medicine, 
Aalborg University, 2Dermato-venereological Department, Bispebjerg 
Hospital, Copenhagen, 3The Allergy Clinic, Copenhagen University Hospi-
tal, Gentofte, Copenhagen, Denmark 
Notalgia paresthetica is a relatively common focal neuropathic itch 
condition (IFSI classification III) manifesting in intense chronic 
or recurrent episodic itch in a hyperpigmented, macular, uni- or 
bilateral skin area frequently located below and/or medially to the 
scapulae. Achieving satisfactory relieve in notalgia paresthetica 
patients is highly challenging. In this case series three female 
notalgia paresthetica patients were treated with 8% capsaicin cap-
saicin patches following a spatial quantification of their alloknetic 
area with a 10 g von Frey filament. The use of a von Frey filament 
in order to delimit the precise area of itch, itch sensitization and 
thus patch application, proved clinically feasible. Although 8% 
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topical capsaicin relieved itch in all three patients, the duration of 
the effectiveness varied greatly from only 2–3 days to >2 months. 
The treatment was well tolerated by the three notalgia paresthe-
tica patients and there appear to be no significant hindrances to 
applying this treatment with notalgia paresthetica as an indication, 
although it may only exhibit satisfactory effectiveness in certain 
patients. Placebo-controlled double-blinded trials are needed to 
confirm the effectiveness of the treatment and assess potential 
predictive parameters of the treatment outcome.
PP26
IMPACT OF PSEUDO-CERAMIDE CONTAINING 
MOISTURIZER ON THE ITCH INTENSITY IN 
SUBJECTS WITH ATOPIC DERMATITIS
Shoko Shindo1, Hiroyuki Murota1, Emi Ono1, Mayuko Tahara1, 
Tsuyoshi Seki2, Katsura Mori2, Kazuhiro Kaizu2, Takahiro Nis-
hizaka2, Ichiro Katayama1
1Department of Dermatology, Course of Integrated Medicine, Graduate 
School of Medicine, Osaka University, Osaka, 2Skin Care Products Re-
search Laboratories, Kao Corporation, Tokyo, Japan
Dry skin in atopic dermatitis (AD) has been thought to contribute 
to cause itch. It has been reported that ceramide-content decreased 
in stratum corneum of AD, and contributes to the skin drynesss. To 
investigate the impact of topical application of ceramide on itch, 
we conducted a randomized placebo-controlled bilateral compa-
rative study. Moisturizers with or without pseudo-ceramide were 
allocated in randomized manner to fore arms (especially cubital 
fossa) of subjects with mild and moderate AD (n=9) for 4 weeks. 
At the point of 0 week, 2 weeks and 4 weeks after initiation of 
this protocol, skin manifestations (e.g, itch VAS score, drynesss, 
erythema, excoriation, water holding capacity ,TEWL, threshold 
temperature and axon reflex-mediated sweating volume measured 
by quantitative sudomotor axon reflex test (QSART)) were eva-
luated. In the result, both pseudo-ceramide containing or placebo 
creams improved drynesss. On the one hand, pseudo-ceramide 
containing cream apparently reduced itch VAS score compared to 
the placebo cream. This indicated that the topical pseudo-ceramide 
application will contribute to itch effectively.
CLINICAL RESEARCH TRACK – 
CLINICAL TRIALS
PP27
HAS SERTACONAZOL 2% AN ANTIPRURITIC 
EFFECT IN ATOPIC DERMATITIS?
Sonja Ständer1, Martin Metz2, Mac H. Ramos F.3, Marcus Mau-
rer2, Nicole Schhoepke2, Athanasios Tsianakas1, Claudia Zeid-
ler1, Thomas A. Luger1
1Competence Center Chronic Pruritus, Department of Dermatology, Uni-
versity Hospital Münster, 2Allergie-Centrum-Charité, Department of Der-
matology and Allergy, Charité –Universitätsmedizin Berlin, Berlin, Ger-
many, 3Galderma-Spirig, Egerkingen Switzerland
Sertaconazole has been reported to have direct immunomodulatory 
effects, which could possibly explain part of its antipruritic effect 
in fungal infections. However, little is known about its antipruritic 
effect in other pruritic skin diseases like e.g. atopic dermatitis. 
Therefore, we conducted a randomized, double-blind, placebo 
controlled, clinical trial to assess the antipruritic effect of topical 
sertaconazole 2% cream in atopic dermatitis patients, who applied 
one of the two treatments twice daily during four weeks on pru-
ritic AD skin. Primary efficacy success was defined as ≥ 2 grades 
pruritus intensity reduction (VRS) between baseline and week 4. 
Further efficacy variables were, pruritus intensity and insomnia 
(both VAS), state of atopic dermatitis (SCORAD) and of quality 
of life (DLQI). 16% of patients in the active group and 21% in the 
placebo group achieved the primary objective. Pruritus intensity 
as evaluated by VAS decreased slightly but not significantly more 
in the active group. Overall, no significant difference between 
sertaconazole 2% and placebo could be observed for any of the 
evaluated itch and itch related parameters.
PP28
IDIOPATHIC PRURITUS AMONG ELDERLY 
FRENCH OUTPATIENTS: CHARACTERISTICS 
AND IMPACT OF AN EMOLLIENT
Jennifer Theunis, Cécile Viode, Ophélie Lejeune, Anne-Marie 
Schmitt, Christiane Casas, Valérie Mengeaud
Pierre Fabre Dermo-Cosmétique, Toulouse, France
The prevalence of pruritus is high among the elderly, but sur-
prisingly has been rarely studied in France. This pilot study was 
performed to describe pruritus among elderly French people and 
to assess the impact of an emollient. 15 patients aged 78.80±9.19 
years suffering from chronic idiopathic pruritus were enrolled. 
46% experienced pruritus at least once per day. The arms were the 
most common sites where patients experienced pruritus (93.3%). 
In most cases (60%), a predisposing factor was found. After 2 
weeks of emollient application, pruritus intensity was decreased 
as measured by VAS (p=0.0015) and a validated questionnaire 
(p<0.0001) and xerosis was improved (4-point grading scale 
(p=0.0002)). Cathepsin S, whose role in some pruritic inflam-
matory dermatoses is described, was assessed by taking cotton 
swab samples of skin on itching sites. Before treatment, Cathepsin 
S levels were similar to those of a population without pruritus 
or xerosis and remained unchanged after 2 weeks of treatment 
(p=0.838) suggesting that Cathepsin S is not involved in pruritus 
in the elderly. This pilot study validated the efficacy of an emol-
lient in reducing pruritus intensity among elderly patients and 
suggested that Cathepsin S is not a relevant marker of pruritus 
in this population.
PP29
THE POSITIVE IMPACT OF MEDITATION 
ON QUALITY OF LIFE FOR PATIENTS WITH 
CHRONIC PRURITUS: A PILOT TRIAL
Alexandra Seamens, Mamta Jhaveri, Kuang-Ho Chen, Suephy 
Chen
Emory University, Atlanta, USA
Background: Chronic itch is a debilitating problem with excee-
dingly few medical therapy options. Meditation has been shown 
to reduce neuroendocrine and inflammatory markers. This study 
investigates the impact of meditation on chronic pruritus and 
quality of life (QoL). Methods: Seven adults with chronic pruritus 
participated in an 8-week meditation course. Four patients (57%) 
completed the course, defined as class attendance >75%. QoL was 
evaluated with a validated, self-reported questionnaire (ItchyQoL) 
before and after the course. The test reports a summative score 
